夜盘异动 | 诺和诺德涨近5%，Q4营收超预期，预测2025年销售额增幅放缓
2月5日，诺和诺德公布财报，财报显示：去年第四季度营业利润增长37%，至367亿丹麦克朗，超过分析师平均预期的336亿丹麦克朗，但预计2025年的销售增长将低于2024年。
公司表示，由于对其减肥药Wegovy和糖尿病药Ozempic的需求减弱，预计今年的销售额增幅将在16%至24%之间，低于一年前的预期。
诺和诺德首席执行官Lars Fruergaard Jorgensen在一份声明中表示：“2025年，我们将继续专注于商业执行、早期和后期研发管道的进展以及产能的扩大。”
财报发布后，诺和诺德美股夜盘涨近5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10